annual CFF:
-$4.93B-$2.48B(-100.86%)Summary
- As of today (July 27, 2025), TAK annual cash flow from financing activities is -$4.93 billion, with the most recent change of -$2.48 billion (-100.86%) on March 1, 2025.
- During the last 3 years, TAK annual CFF has risen by +$4.60 billion (+48.25%).
- TAK annual CFF is now -118.56% below its all-time high of $26.58 billion, reached on March 31, 2019.
Performance
TAK Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$1.99B+$2.35B(+54.22%)Summary
- As of today (July 27, 2025), TAK quarterly cash flow from financing activities is -$1.99 billion, with the most recent change of +$2.35 billion (+54.22%) on March 1, 2025.
- Over the past year, TAK quarterly CFF has dropped by -$1.54 billion (-341.15%).
- TAK quarterly CFF is now -114.13% below its all-time high of $14.05 billion, reached on March 31, 2019.
Performance
TAK quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$4.93B-$1.54B(-45.19%)Summary
- As of today (July 27, 2025), TAK TTM cash flow from financing activities is -$4.93 billion, with the most recent change of -$1.54 billion (-45.19%) on March 1, 2025.
- Over the past year, TAK TTM CFF has dropped by -$2.48 billion (-100.86%).
- TAK TTM CFF is now -118.56% below its all-time high of $26.58 billion, reached on March 31, 2019.
Performance
TAK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TAK Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -100.9% | -341.1% | -100.9% |
| 3 y3 years | +48.3% | +12.3% | +48.3% |
| 5 y5 years | +46.7% | -49.5% | +47.6% |
TAK Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.9% | +48.3% | -197.8% | +54.2% | -1707.8% | +33.7% |
| 5 y | 5-year | -100.9% | +52.0% | -197.8% | +54.2% | -1707.8% | +59.9% |
| alltime | all time | -118.6% | +52.0% | -114.1% | +66.6% | -118.6% | +59.9% |
TAK Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | -$4.93B(+100.9%) | -$1.99B(-54.2%) | -$4.93B(+45.2%) |
| Dec 2024 | - | -$4.34B(+577.3%) | -$3.40B(-1207.4%) |
| Sep 2024 | - | -$640.38M(-131.6%) | $306.83M(-5700.9%) |
| Jun 2024 | - | $2.03B(-550.9%) | -$5.48M(-99.8%) |
| Mar 2024 | -$2.46B(-53.2%) | -$450.06M(-28.8%) | -$2.46B(+8.0%) |
| Dec 2023 | - | -$632.25M(-33.6%) | -$2.27B(-51.5%) |
| Sep 2023 | - | -$952.69M(+126.3%) | -$4.69B(+17.0%) |
| Jun 2023 | - | -$421.06M(+56.9%) | -$4.01B(-23.7%) |
| Mar 2023 | -$5.25B(-44.9%) | -$268.38M(-91.2%) | -$5.25B(-27.5%) |
| Dec 2022 | - | -$3.05B(+1018.9%) | -$7.25B(+32.0%) |
| Sep 2022 | - | -$272.26M(-83.6%) | -$5.49B(-26.3%) |
| Jun 2022 | - | -$1.66B(-26.4%) | -$7.44B(-21.9%) |
| Mar 2022 | -$9.53B(-7.1%) | -$2.26B(+75.7%) | -$9.53B(-10.6%) |
| Dec 2021 | - | -$1.29B(-42.1%) | -$10.66B(-13.4%) |
| Sep 2021 | - | -$2.23B(-40.7%) | -$12.31B(+0.6%) |
| Jun 2021 | - | -$3.76B(+10.8%) | -$12.23B(+19.1%) |
| Mar 2021 | -$10.27B(+11.0%) | -$3.39B(+15.4%) | -$10.27B(+25.1%) |
| Dec 2020 | - | -$2.94B(+36.6%) | -$8.21B(+46.0%) |
| Sep 2020 | - | -$2.15B(+20.0%) | -$5.62B(-40.3%) |
| Jun 2020 | - | -$1.79B(+34.9%) | -$9.42B(+1.9%) |
| Mar 2020 | -$9.25B(-134.8%) | -$1.33B(+275.8%) | -$9.25B(-250.9%) |
| Dec 2019 | - | -$353.41M(-94.1%) | $6.13B(-69.2%) |
| Sep 2019 | - | -$5.95B(+268.0%) | $19.88B(-22.7%) |
| Jun 2019 | - | -$1.62B(-111.5%) | $25.71B(-3.2%) |
| Mar 2019 | $26.58B(-1002.6%) | $14.05B(+4.9%) | $26.58B(+138.5%) |
| Dec 2018 | - | $13.40B(<-9900.0%) | $11.14B(-492.1%) |
| Sep 2018 | - | -$118.49M(-84.3%) | -$2.84B(-2.3%) |
| Jun 2018 | - | -$753.32M(-45.6%) | -$2.91B(-1.3%) |
| Mar 2018 | -$2.94B(-209.8%) | -$1.38B(+136.2%) | -$2.94B(-453.9%) |
| Dec 2017 | - | -$585.80M(+217.7%) | $831.87M(+11.3%) |
| Sep 2017 | - | -$184.37M(-76.7%) | $747.52M(-12.0%) |
| Jun 2017 | - | -$790.50M(-133.0%) | $849.16M(-68.3%) |
| Mar 2017 | $2.68B | $2.39B(-457.0%) | $2.68B(+355.5%) |
| Dec 2016 | - | -$670.16M(+710.0%) | $588.57M(-18.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2016 | - | -$82.73M(-107.9%) | $722.47M(+1.1%) |
| Jun 2016 | - | $1.04B(+246.5%) | $714.37M(-168.7%) |
| Mar 2016 | -$1.04B(-62.2%) | $300.42M(-156.0%) | -$1.04B(-60.2%) |
| Dec 2015 | - | -$536.25M(+490.3%) | -$2.61B(+3.1%) |
| Sep 2015 | - | -$90.84M(-87.3%) | -$2.54B(-5.7%) |
| Jun 2015 | - | -$713.66M(-43.9%) | -$2.69B(-2.3%) |
| Mar 2015 | -$2.75B(-385.7%) | -$1.27B(+177.8%) | -$2.75B(+71.5%) |
| Dec 2014 | - | -$458.27M(+87.0%) | -$1.60B(-11.3%) |
| Sep 2014 | - | -$245.10M(-68.4%) | -$1.81B(-316.6%) |
| Jun 2014 | - | -$775.89M(+519.5%) | $834.97M(-13.3%) |
| Mar 2014 | $963.50M(-152.3%) | -$125.25M(-81.1%) | $963.50M(-11.5%) |
| Dec 2013 | - | -$662.29M(-127.6%) | $1.09B(-37.8%) |
| Sep 2013 | - | $2.40B(-470.5%) | $1.75B(-370.5%) |
| Jun 2013 | - | -$647.36M(+1354.6%) | -$647.36M(-62.0%) |
| Mar 2013 | -$1.84B(-136.9%) | - | - |
| Mar 2012 | $4.99B(-393.1%) | - | - |
| Mar 2011 | -$1.70B(+6.7%) | -$44.50M(-94.5%) | -$1.70B(-1.6%) |
| Dec 2010 | - | -$807.49M(+412.8%) | -$1.73B(+4.6%) |
| Sep 2010 | - | -$157.47M(-77.3%) | -$1.65B(+2.2%) |
| Jun 2010 | - | -$692.50M(+868.4%) | -$1.62B(+1.4%) |
| Mar 2010 | -$1.60B(-62.7%) | -$71.51M(-90.2%) | -$1.60B(+4.7%) |
| Dec 2009 | - | -$731.82M(+497.4%) | -$1.52B(+92.4%) |
| Sep 2009 | - | -$122.50M(-81.7%) | -$792.25M(+18.3%) |
| Jun 2009 | - | -$669.75M | -$669.75M |
| Mar 2009 | -$4.28B(+86.2%) | - | - |
| Mar 2008 | -$2.30B(-14.9%) | - | - |
| Mar 2007 | -$2.70B(+242.2%) | - | - |
| Mar 2006 | -$789.71M(+14.7%) | - | - |
| Mar 2005 | -$688.75M(+30.8%) | - | - |
| Mar 2004 | -$526.51M(+8.6%) | - | - |
| Mar 2003 | -$484.60M(+14.9%) | - | - |
| Mar 2002 | -$421.79M(+11.1%) | - | - |
| Mar 2001 | -$379.79M(+50.9%) | - | - |
| Mar 2000 | -$251.64M | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash flow from financing activities?
- What is the all time high annual CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual CFF year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly CFF year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM CFF year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash flow from financing activities?
The current annual CFF of TAK is -$4.93B
What is the all time high annual CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash flow from financing activities is $26.58B
What is Takeda Pharmaceutical Company Limited annual CFF year-on-year change?
Over the past year, TAK annual cash flow from financing activities has changed by -$2.48B (-100.86%)
What is Takeda Pharmaceutical Company Limited quarterly cash flow from financing activities?
The current quarterly CFF of TAK is -$1.99B
What is the all time high quarterly CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash flow from financing activities is $14.05B
What is Takeda Pharmaceutical Company Limited quarterly CFF year-on-year change?
Over the past year, TAK quarterly cash flow from financing activities has changed by -$1.54B (-341.15%)
What is Takeda Pharmaceutical Company Limited TTM cash flow from financing activities?
The current TTM CFF of TAK is -$4.93B
What is the all time high TTM CFF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM cash flow from financing activities is $26.58B
What is Takeda Pharmaceutical Company Limited TTM CFF year-on-year change?
Over the past year, TAK TTM cash flow from financing activities has changed by -$2.48B (-100.86%)